Advancing Alzheimer’s Diagnostics: Insights from ALZpath VP of R&D Dr. Lee Honigberg on the Future of Blood-Based Biomarker Assays

In this episode, Ayesha spoke with Lee Honigberg, PhD, VP of Research & Development, ALZpath, a provider of diagnostic tools for Alzheimer’s disease. 

 

This includes a blood-based biomarker assay, called the ALZpathDx assay, which measures pTau217 in the blood.

Prior to joining ALZpath, Dr. Honigberg was most recently Senior Director and Distinguished Scientist in Translational Medicine at Genentech, where he was leading a group responsible for biomarker development for programs in neuroscience, ophthalmology, cardiovascular and metabolic disease.

Before Genentech, Dr. Honigberg was at Pharmacyclics where he led the preclinical development of ibrutinib, the first approved BTK inhibitor, establishing a new standard of treatment in chronic lymphocytic leukemia (CLL).

Dr. Honigberg’s contributions were recognized by the 2019 ACS Heroes in Chemistry award. Dr. Honigberg received a PhD in Neuroscience from the University California San Francisco (UCSF).

Tune into to the episode to learn about the latest innovations in Alzheimer’s diagnostics.

For more life science and medical device content, visit the Xtalks Vitals homepage. https://xtalks.com/vitals/

Follow Us on Social Media

Twitter: https://twitter.com/Xtalks
Instagram: https://www.instagram.com/xtalks/
Facebook: https://www.facebook.com/Xtalks.Webinars/
LinkedIn: https://www.linkedin.com/company/xtalks-webconferences
YouTube: https://www.youtube.com/c/XtalksWebinars/featured